YIH
IART icon

Y-Intercept (HK)’s Integra LifeSciences IART Stock Holding History

Y-Intercept (HK)’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,333
Closed -$934K – 1612
2024
Q1 		$934K Buy
26,333
+6,761
+35% +$270K 0.07% 416
2023
Q4 		$852K Buy
+19,572
New +$770K 0.08% 375
2023
Q3 		– Sell
-10,846
Closed -$446K – 1288
2023
Q2 		$446K Buy
10,846
+1,797
+20% +$86.5K 0.05% 599
2023
Q1 		$520K Buy
9,049
+3,750
+71% +$211K 0.06% 511
2022
Q4 		$297K Sell
5,299
-18,867
-78% -$960K 0.04% 659
2022
Q3 		$1.02M Buy
24,166
+6,976
+41% +$357K 0.1% 296
2022
Q2 		$929K Buy
17,190
+3,988
+30% +$240K 0.12% 252
2022
Q1 		$848K Buy
13,202
+7,517
+132% +$495K 0.19% 148
2021
Q4 		$381K Buy
+5,685
New +$385K 0.09% 323

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Y-Intercept (HK)'s IART Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 26,333 shares — an estimated $934K sold.

Y-Intercept (HK) first reported a position in IART in Q4 2021 and held it in 9 quarters. The position peaked at $1.02M in Q3 2022. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

  • Y-Intercept (HK) reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 26,333 Integra LifeSciences shares in Q2 2024, an estimated $934K.
  • Y-Intercept (HK) first reported a position in Integra LifeSciences in Q4 2021 and held it in 9 quarters.
  • Y-Intercept (HK)'s Integra LifeSciences position peaked at $1.02M in Q3 2022.
  • 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.